Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Company profile
Ticker
XBIO
Exchange
Website
CEO
Jeffrey F. Eisenberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GENERAL AIRCRAFT INC., General Sales & Leasing, Inc.
SEC CIK
Corporate docs
Subsidiaries
Xenetic Biosciences (UK), Ltd. • Lipoxen Technologies, Ltd. • Xenetic Bioscience, Inc. • SymbioTec, GmbH • Hesperix S.A. ...
XBIO stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
22 Dec 22
8-K
Submission of Matters to a Vote of Security Holders
9 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Dec 22
8-K
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
DEFA14A
Additional proxy soliciting materials
17 Oct 22
DEF 14A
Definitive proxy
17 Oct 22
D
$488.84 k in equity, sold $488.84 k, 1 investor
13 Oct 22
8-K
Unregistered Sales of Equity Securities
12 Oct 22
PRE 14A
Preliminary proxy
3 Oct 22
Latest ownership filings
4
ALEXEY ANDREEVICH VINOGRADOV
9 Dec 22
4
Adam Logal
9 Dec 22
4
Roger D. Kornberg
9 Dec 22
4
Firdaus J. Dastoor
9 Dec 22
4
James Eric Callaway
9 Dec 22
4
Grigory G. Borisenko
9 Dec 22
SC 13G
CLS Therapeutics, LLC
21 Oct 22
4
JEFFREY F EISENBERG
28 Mar 22
4
JAMES F PARSLOW
28 Mar 22
4
Curtis Lockshin
28 Mar 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 13.85 mm | 13.85 mm | 13.85 mm | 13.85 mm | 13.85 mm | 13.85 mm |
| Cash burn (monthly) | 359.76 k | 487.88 k | 282.60 k | 585.72 k | 359.76 k | 446.21 k |
| Cash used (since last report) | 1.56 mm | 2.12 mm | 1.23 mm | 2.55 mm | 1.56 mm | 1.94 mm |
| Cash remaining | 12.28 mm | 11.73 mm | 12.62 mm | 11.30 mm | 12.28 mm | 11.91 mm |
| Runway (months of cash) | 34.1 | 24.0 | 44.7 | 19.3 | 34.1 | 26.7 |
Institutional ownership, Q3 2022
6.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 15 |
| Opened positions | 2 |
| Closed positions | 2 |
| Increased positions | 2 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 516.00 k |
| Total shares | 957.94 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 616.47 k | $331.00 k |
| Renaissance Technologies | 115.10 k | $62.00 k |
| Geode Capital Management | 92.60 k | $49.00 k |
| JTC Employer Solutions Trusteee | 26.99 k | $15.00 k |
| Virtu Financial | 19.73 k | $11.00 k |
| Steward Partners Investment Advisory | 19.00 k | $10.00 k |
| NTRS Northern Trust | 17.76 k | $10.00 k |
| Two Sigma Securities | 13.96 k | $8.00 k |
| Tower Research Capital | 11.69 k | $6.00 k |
| Great Valley Advisor | 10.60 k | $6.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Dec 22 | Firdaus J. Dastoor | Stock Options Common Stock | Grant | Acquire A | No | No | 0.4367 | 25,000 | 10.92 k | 25,000 |
| 7 Dec 22 | Borisenko Grigory G. | Stock Options Common Stock | Grant | Acquire A | No | No | 0.4367 | 25,000 | 10.92 k | 25,000 |
| 7 Dec 22 | Logal Adam | Stock Options Common Stock | Grant | Acquire A | No | No | 0.4367 | 25,000 | 10.92 k | 25,000 |
| 7 Dec 22 | Kornberg Roger D. | Stock Options Common Stock | Grant | Acquire A | No | No | 0.4367 | 25,000 | 10.92 k | 25,000 |
| 7 Dec 22 | James Eric Callaway | Stock Options Common Stock | Grant | Acquire A | No | No | 0.4367 | 25,000 | 10.92 k | 25,000 |
News
12 Health Care Stocks Moving In Monday's Intraday Session
6 Feb 23
12 Health Care Stocks Moving In Monday's After-Market Session
19 Dec 22
Stocks That Hit 52-Week Lows On Friday
16 Dec 22
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
30 Nov 22
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
16 Nov 22
Press releases
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy
17 Jan 23
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
11 Jan 23
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event
5 Jan 23
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform
16 Nov 22